• Gastroent Hepat Barc · Nov 2018

    Multicenter Study Observational Study

    Vedolizumab, an option in patients with inflammatory bowel disease intolerant to thiopurines and refractory to biological agents.

    • Marisa Iborra, Belén Beltrán, Nuria Maroto, Pablo Navarro-Cortés, Maia Boscá-Watts, Isabel Ferrer-Bradley, Natalia García-Morales, Esteban Sáez-González, Joaquín Hinojosa, Miguel Mínguez, and Pilar Nos.
    • Departamento de Gastroenterología, Hospital Universitari i Politecnic La Fe, CiberEHD, Valencia, España.
    • Gastroent Hepat Barc. 2018 Nov 1; 41 (9): 535-543.

    AbstractVedolizumab (VDZ), a human monoclonal antibody that binds specifically to α4β7-integrin, and is approved for the treatment of Crohn's disease (CD) and ulcerative colitis (UC), has demonstrated its efficacy in controlled clinical trials.Copyright © 2018 Elsevier España, S.L.U. All rights reserved.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…